Evidence map›Paper›PMID 32542007›Full record

ArticlePloS one2020

The clinical value of peripheral immune cell counts in pancreatic cancer.

Osama Abu-Shawer, Mohammad Abu-Shawer, Abdullah Shurman, Ali Lattouf, Ayman Haimour, Omar Hamdan, Razan Mansour, Tamer Altamimi, Maysa Al-Hussaini

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Eosinophils in solid cancers: sentinels, predictors, and therapeutic allies.Journal of experimental & clinical cancer research : CR · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Osama Abu-ShawerHarvard Medical School, Boston, MA, United States of America.
Mohammad Abu-ShawerIstiklal Hospital, Amman, Jordan.
Abdullah ShurmanUniversity of Jordan School of Medicine, Amman, Jordan.
Ali LattoufUniversity of Jordan School of Medicine, Amman, Jordan.
Ayman HaimourDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, Canada.
Omar HamdanUniversity of Jordan School of Medicine, Amman, Jordan.
Razan MansourUniversity of Jordan School of Medicine, Amman, Jordan.
Tamer AltamimiUniversity of Jordan School of Medicine, Amman, Jordan.
Maysa Al-HussainiDepartment of Pathology and Laboratory Medicine, King Hussein Cancer Centre, Amman, Jordan.ORCID 0000-0001-6392-150X
University of Jordan · JOHarvard University · USJordan Hospital · JOKing Hussein Cancer Center · JOUniversity of Victoria · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundElevated neutrophil-lymphocyte ratio (NLR) is linked to poor overall survival (OS) in pancreatic cancer. We aim to investigate the association of the various hematologic markers, in particular NLR among others, with distant metastases, a common feature in pancreatic cancer.

methodsClinical data from 355 pancreatic cancer patients managed at King Hussein Cancer Center (Amman-Jordan) have been reviewed. We examined the relationship between absolute neutrophil count (ANC), absolute lymphocyte count (ALC), absolute eosinophilic count (AEC), absolute monocytic count (AMC), NLR, monocyte to lymphocyte ratio (MLR) and platelet to lymphocyte ratio (PLR) with the presence of baseline distant metastases and OS. Receiver Operating Characteristic (ROC) curve analysis was plotted to identify the NLR optimum cutoff value indicative of its association with distant metastases.

resultsOn univariate and multivariate analyses patients whom on presentation had high NLR (≥3.3) showed more baseline distant metastases compared to patients with low NLR (<3.3), (p-value: <0.0001 and <0.0001, respectively). Patients with high baseline ANC (≥5500/μL), AMC (≥600/μL), MLR (≥0.3) had more baseline distant metastases in comparison to patients with lower values (p-value: 0.02, 0.001, and <0.0001, respectively). High ANC, NLR, MLR, and PLR and low ALC were associated with poorer OS, (p-value: <0.0001, <0.0001, <0.0001, 0.04, and 0.01, respectively).

conclusionThis study presents additional evidence of the association of some of the hematologic markers; in particular ANC, NLR, AMC, and MLR, with baseline distant metastases and poor outcome in pancreatic cancer. Whether these immune phenomena can help in identifying patients at higher risk for the subsequent development of distant metastases is unknown.

Indexed as

AgedArea Under CurveBlood Cell CountFemaleHumansKaplan-Meier EstimateLymphocytesMaleMiddle AgedNeoplasm MetastasisNeutrophilsPancreatic NeoplasmsRetrospective StudiesROC Curve

Identifiers

PMID32542007
PMCPMC7295193
OpenAlexW3034859209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.